Latest News Release
RH Nanopharmacuticals submits IND application to U.S. FDA for RHN001 AND RHN002 for Phase 1 Clinical study in healthy volunteers- May 13, 2021 RH Nanopharmacuticals, LLC announces that the U.S. Food and Drug Administration (FDA) has accepted Investigational drug application (IND) on May 13, 2021 for Phase 1 Clinical study in healthy volunteers. Joel, Ross MD, CEO and Cofounder of RH Nanopharmacuticals, mentioned" This is a milestone we have been waiting for. We are now planning to start testing of formulated RHN001 and RHN002 in humans for multiple indications including orphan diseases. Both drug assets have a potential for a safe and effective alternative to current analgesics and likely opioid sparing, Dr Ross said. Phase 1 study will be initiated very soon, said Izhar Hasan, MD PhD, Chief Scientific Officer and Principal Investigator of the clinical study at RHNanopharma.
